Comprehensive Analysis Of All 2014 Clinical Trial Activity At Top Pharma Early-Release At IIR’s Partnerships In Clinical Trials Conference Today

Citeline 2014 Clinical Trials Roundup Analyzing State of Clinical Trials for Unapproved Drugs by Sponsor, Disease, Geography and More Now Available Exclusively to PCT Attendees

Partnerships in Clinical Trials is produced by IIR; April 22-24, 2015; Boston, MA; www.clinicaltrialpartnerships.com

BOSTON--(BUSINESS WIRE)--Citeline—the leading provider of intelligence on pharmaceutical industry R&D—today early-released its highly-anticipated annual “Clinical Trials Roundup” report exclusively to attendees at the 24^th Annual Partnerships in Clinical Trials (“PCT”) conference in Boston, MA. The report captures and analyzes all clinical trial activity for unapproved drugs at the world’s top pharmaceutical companies for the year 2014.

“AstraZeneca was notable last year for starting more clinical trials than any other company, despite spending billions of dollars less than its peers on R&D, which suggests they’re outperforming the industry on a number of fronts in clinical research”

Partnerships in Clinical Trials attendees, who are receiving the Clinical Trials Roundup in advance of its April 27 full release, are now the first in the industry to have access to this comprehensive overview of the state of clinical trials for the year 2014 for unapproved drugs, which includes data on the number of trials started, by whom, for what therapeutic area and disease and where.

The report also examines how much companies are investing in R&D relative to sales revenue, how much of that spend goes to new and ongoing trials and which companies appear to be getting the most mileage from their clinical trials investments.

According to Citeline Vice President of Product Management & Market Strategy Tracy DeGregorio, who authored the report, the numbers are a strong indicator of a company’s strategic discipline.

“AstraZeneca was notable last year for starting more clinical trials than any other company, despite spending billions of dollars less than its peers on R&D, which suggests they’re outperforming the industry on a number of fronts in clinical research,” said DeGregorio.

“Celgene also stood out for pumping approximately 35% of sales revenue back into R&D, indicating a very high level of confidence in its development strategy,” DeGregorio added.

The 2014 Clinical Trials Roundup encompasses more than 2900 trials worldwide by 20 leading pharmaceutical companies across six major therapeutic areas—autoimmune/inflammation, cardiovascular, CNS, infectious disease, metabolic/endocrinology, and oncology—accounting for more than 180 diseases.

According to PCT Conference Director Marina Adamsky, the report provides an additional intelligence edge for Partnerships in Clinical Trials attendees.

“Citeline’s Clinical Trials Roundup identifies key trends in clinical trials by therapeutic area, disease and geography and offers unique insight into where companies are placing their strategic bets,” said Adamsky.

“Having early access to this report ensures that the decision makers working in clinical research, operations and trials who attend Partnerships in Clinical Trials will have another valuable window into the market to inform their discussions with partners and industry peers at the conference and an important information asset to take home with them,” Adamsky said.

Citeline’s 2014 Clinical Trials Roundup will be available to the public on April 27, 2015 at https://citeline.com/category/whitepapers/.

ABOUT CITELINE

Citeline is the world’s most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched data collection of global clinical trials, clinical trial investigator profiles and drug development pipelines drawn from over 30,000 unique sources and analyzed by the industry’s largest team of expert analysts and editors. Citeline clients include 19 of the world’s top 20 pharmaceutical companies.

For more information, please visit: https://citeline.com/

ABOUT PARTNERSHIPS IN CLINICAL TRIALS

With 24 years serving professionals in clinical development and operations, trials and outsourcing, Partnerships in Clinical Trials is the world’s foremost annual event for clinical development leaders and practitioners. More than 1100 attendees representing more than 125 pharma, biotech and medical device companies, CROs and third-party suppliers from nearly 50 countries attend PCT annually to network, learn, strategize and advance next practices in clinical trials across the globe. Partnerships in Clinical Trials is produced by the Institute for International Research (IIR) and committed to redefining clinical research excellence on a global scale.

Partnerships in Clinical Trials 2015 taking place April 22-24 in Boston, MA, features more than 130 speakers in keynotes and across eight specialized breakout tracks with exciting new unfiltered, unscripted and unedited formats spanning think tanks, case insights, intensives, and other interactive sessions, alongside results-oriented, innovative networking opportunities and special events like the 4^th Annual Women’s Clinical Leadership Forum.

For more information, please visit: www.clinicaltrialpartnerships.com

Help employers find you! Check out all the jobs and post your resume.